Intrexon | XON - Ordinary Share Capital


Intrexon reported $0 in Ordinary Share Capital for its fiscal quarter ending in June of 2024.





Ordinary Share Capital Change Date
Agenus USD 35.32M 2.51M Dec/2025
Alaunos Therapeutics USD 2.38M 172K Mar/2026
Amgen USD 540M 1000K Mar/2026
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 137.39M 1.69M Dec/2025
AstraZeneca USD 1.55B 73K Mar/2026
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Gilead Sciences USD 1.24B 1000K Mar/2026
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Incyte USD 199.95M 1.49M Mar/2026
Intrexon USD 0 0 Jun/2024
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
MacroGenics USD 63.32M 60K Dec/2025
MannKind USD 308.91M 1.07M Mar/2026
Merck USD 2.47B 12.72M Dec/2025
Novartis USD 1.91B 60K Mar/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Roche Holding CHF 795.62M 699.54K Dec/2025
Thermo Fisher Scientific USD 371.62M 4.09M Mar/2026
Veracyte USD 79.79M 743K Mar/2026
Xencor USD 74.06M 2.19M Mar/2026